
Shares of Medtronic (NYSE: MDT) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device company announced its fiscal 2025 third-quarter results before the market opened.
Medtronic reported third-quarter revenue of $8.3 billion, up 2.5% year over year. This result came in slightly below the consensus Wall Street estimate of $8.33 billion. Diluted earnings per share (EPS) were $1.01 based on generally accepted accounting principles (GAAP). Its adjusted EPS was $1.39, up 7% year over year and higher than the average analysts' estimate of $1.35.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Investors clearly focused more on the lower-than-expected revenue than the better-than-expected earnings. But just how worrisome is the company's revenue miss?
I don't think it's worrisome at all. CEO Geoff Martha explained in the earnings call that surgical revenue was hurt by "a change in U.S. distributor buying patterns." However, Martha said this disruption is expected to be resolved soon.
Importantly, Medtronic continues to project organic revenue growth in fiscal 2025 of between 4.75% and 5%. It also expects adjusted EPS in the current fiscal year of $5.44 to $5.50. The midpoint of this range is above the consensus Wall Street EPS estimate of $5.45.
Investors seeking strong growth probably won't find the company appealing even with its shares down following the third-quarter update. However, the stock could be attractive to income investors. Its forward dividend yield is 3.24%.
Medtronic also isn't far away from potentially joining the elite group known as Dividend Kings with its track record of 47 consecutive years of dividend increases.
Before you buy stock in Medtronic, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medtronic wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $850,946!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 7, 2025
Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy.